Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Some investors are staying away from the market right now due to the volatility stocks have experienced this year and the ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 billion, ...

Shares of Vertex Pharmaceuticals tumbled 10% to close at 450.03. Shares undercut their 50-day and 200-day moving averages, though the stock is still consolidating with a buy point at 519.88 ...

The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff policies and prepared for tomorrow’s Federal Reserve announcement.

The stock's fall snapped a four-day winning streak.